Friday, July 31, 2026

Understanding the Latest North-South Drone Dispute: Key Insights and Implications

South Korea convenes NSC after North Korea claims a drone incursion, which South Korea denies, prompting an investigation by President Lee.

Toyota vs Volkswagen: Who Dominates Global Car Sales in 2025?

Volkswagen's 2025 global sales fell 0.5%, while Toyota remains the top automaker with 10.32 million vehicles sold, outperforming VW.

Xi Jinping to Host Kim Jong Un in Beijing for War Victory Celebrations

Kim Jong Un's upcoming visit to China highlights diplomatic efforts and improved North Korea-China relations, according to Rodong Sinmun.

Tag: biosimilars

North KoreaKoreaKimMilitaryAISouth KoreamarketrelationsInternational

Celltrion Files for European Approval of Cosentyx Biosimilar, Targets $6.7 Billion Market

Celltrion has filed for European approval of its CT-P55 biosimilar for autoimmune diseases, aiming for early market entry and expansion.

How Celltrion’s Truxima Dominates the U.S. Rituximab Market: A 4-Month Winning Streak

Celltrion's Truxima leads the U.S. rituximab market for four months, gaining FDA interchangeability status, boosting growth prospects.

South Korea Eases Phase 3 Trial Requirements for Biosimilars Following U.S. and EU… Early Data Becomes Key Battleground

South Korea's MFDS eases Phase 3 trial requirements for biosimilars, aligning with global trends, enhancing early comparability importance.

How Celltrion’s Omlyclo Achieved 16% Market Share in Europe: A Game-Changer for Biologics

Celltrion's biosimilars gain market share in Europe, with Omlyclo leading in Spain and Vegzelma maintaining strong presence amid competition.

Interview: Huons’ PanGen Bets on ‘Development-Focused CDMO’ Strategy Built on Biosimilar Experience

South Korea's PanGen CDMO emphasizes development expertise and tailored services, enhancing drug development support for clients.

Celltrion Launches New Autoimmune Drug Avtozma in Japan

Celltrion launches Avtozma for autoimmune diseases in Japan, expanding its product portfolio and strengthening market presence.

Celltrion’s Steqeyma IV Approval: What This Means for Celltrion’s Growth in Japan’s Autoimmune Drug Market

Celltrion's Steqeyma IV formulation gains approval in Japan, expanding treatment for Crohn's disease and enhancing market competitiveness.

Truxima: How the First Korean Biosimilar Achieved 35.8% Market Share in the U.S.!

Celltrion’s Truxima becomes South Korea's first biosimilar to lead U.S. prescription market, boosted by tariff exemptions and strong growth.

How Celltrion’s Local Production Strategy Eliminates U.S. Drug Tariffs Influence

Celltrion resolves tariff impacts on U.S. sales, boosting local production and growth opportunities for its biosimilars, including Zymfentra.

Samchundang Pharm Announces 250 Billion KRW Stake Sale…Expectations Rise for Future Growth

Samchundang Pharm's CEO plans a 2.5 billion KRW share sale for tax purposes, hinting at significant news and future growth in pharma.

Celltrion’s 1 Trillion KRW Investment: A Game Changer for Biopharmaceutical Production by 2030

Celltrion plans a major expansion with over 1 trillion KRW investment, boosting production capacity for biosimilars and new drugs by 2030.

Why Celltrion’s STEQEYMA Auto-Injector is a Game Changer for Autoimmune Patients in North America

Celltrion expands its Steqeyma auto-injector lineup in Canada, enhancing market competitiveness and patient accessibility in North America.

Celltrion’s Breakthrough: Why Vegzelma and Herzuma Lead in Japan’s Oncology Market

Celltrion's cancer treatments dominate the Japanese market, with Vegzelma and Herzuma capturing significant shares, showcasing strong growth.

How Celltrion Plans to Cut Biologics Development Costs by 25% Amid FDA Regulation Changes

Celltrion is optimistic about enhanced competitiveness due to eased biosimilar regulations by the FDA, expecting significant cost reductions.

Top News

- Our Sponsors Ad -

Follow us

Cars

Tech

future

health

© Copyright by News1. All Rights Reserved.